When the Quality Rulebook Changes, the Work Is Not Done — It Is Just Different
The CY2027 MA Stars final rule eliminates 11 measures, reverses the health equity index, and projects over $18 billion in additional bonus payments. For compliance and quality teams, the windfall story is the simpler part.
A Good Day for Insurers. A More Complicated Day for Compliance.
The April 2, 2026 finalization of CMS’s CY2027 Medicare Advantage and Part D rule landed as good news for most MA plans. Eleven quality measures were eliminated. The Health Equity Index — a Biden-era reward mechanism designed to credit plans for improving outcomes among high-risk sub-populations — was reversed before it ever took effect. In its place, the historical reward factor returned, benefiting plans with consistently high overall ratings. CMS projects the changes will add more than $18 billion in bonus payments to the Medicare Advantage program over the next decade, a significant revision upward from the $13 billion estimate in the proposed rule.
Financial analysts and trade associations responded accordingly. The rule was a meaningful reprieve for plans navigating shrinking margins, declining star ratings, and a RADV audit environment that is simultaneously becoming more aggressive.
For compliance teams, quality officers, and operations leads, the story is less straightforward. When CMS restructures the measurement framework, plans do not only collect a higher rebate. They inherit a set of governance and operational questions that do not resolve themselves.
Medicare Advantage quality bonus payments in 2025 alone — up from $3 billion in 2015. 75% of MA enrollees are in plans receiving bonuses. The CY2027 rule adds more to that figure over the next decade. This is the scale of the program that the measure changes are reshaping.
GAP
RISK
Stars No Longer Tracks These Areas. Audits Still Do.
The 11 measures CMS eliminated measured real operational areas — call center access, appeal timeliness, provider satisfaction. Those areas did not disappear from the regulatory landscape. They moved from a public rating consequence to a program audit consequence. That is a meaningful distinction for compliance planning.
The call center measure had become a source of significant plan litigation. Both UnitedHealthcare and Humana challenged star ratings decisions partly on the basis of call center scoring methodology. Removing a contested measure that functions more as a legal liability than a quality signal has operational logic.
But CMS’s reasoning for removing a measure from stars — that plans perform similarly and the measure offers little differentiation for beneficiaries — is not a statement that the underlying operational standard no longer applies. It is a statement that the star ratings system is the wrong instrument to enforce it.
The enforcement instrument that remains is the Part C and D program audit. The Organization Determination, Appeals, and Grievances audit protocol specifically reviews plan timeliness and accuracy. Appeals measures are among the most consequential findings in the program audit framework — and plans with prior findings are already subject to closer review cycles.
Plans should map each of the 11 eliminated measures against the audit protocols that still cover the same operational areas before reducing investment or staffing in those functions. The performance bar has not moved. The reporting mechanism has.
The Health Equity Infrastructure Question No One Is Publicly Discussing
The HEI reversal requires a closer look. CMS is not just choosing not to implement a new reward. It is specifically rescinding the requirements for MA quality improvement programs to include activities designed to reduce health disparities. It is eliminating the health equity expert requirement from utilization management committees. And it is removing both the annual health equity analysis requirement and the public posting obligation.
These were not minor administrative requirements. Plans invested in building health equity infrastructure — staffing UM committees with qualified members, designing disparities analyses, establishing public disclosure workflows. Some did so in good faith well before the HEI took effect. Others built to meet audit expectations rather than scoring incentives. The rule now eliminates the regulatory basis for those requirements.
That creates a governance decision, not just a compliance cleanup. Plans that built these frameworks must now decide what to retain and what to dismantle — and on whose authority. The rule removes a federal mandate. It does not remove the question of whether equity-informed utilization management is clinically or legally prudent given OCR oversight, state insurance department expectations, and the documented pattern of disparities in MA plan performance that federal data sources have consistently confirmed.
The answer is not obvious. Plans that eliminate health equity infrastructure entirely may face scrutiny under OCR civil rights enforcement, state fair insurance laws, and future litigation contexts that the star ratings system never governed. Plans that maintain it without a documented rationale are spending money on a program with no regulatory anchor. The correct response requires deliberate governance discussion at the board or committee level — not a quiet withdrawal from compliance programs that no longer appear on a scorecard.
The sustainability question that the CY2027 windfall defers — but does not answer — is whether bonus payments are producing demonstrably better clinical outcomes at the population level. KFF’s analysis of the quality bonus program found that bonus payments totaled at least $12.7 billion in 2025, more than four times the $3 billion paid in 2015.
With the CY2027 rule projected to add another $18 billion over the next decade, the program’s total cost will inevitably attract scrutiny from MedPAC, GAO, and legislators looking for Medicare savings. The question those reviewers will ask is not whether star ratings went up. It is whether health outcomes improved proportionally.
Plans that earn higher ratings in 2029 and beyond — and that can document the clinical rationale — will be positioned to defend the program in the next regulatory cycle. Plans that inflate ratings by managing to a simplified measure set without underlying quality improvement will not.
Three Work Streams Plans Are Not Fully Pricing In
The CY2027 final rule adds one new measure: a Part C Depression Screening and Follow-Up metric, effective for the 2027 measurement year. Because of the standard two-year lag in the star ratings methodology, this measure will not appear in the five-star rating until 2029. Plans interpreting this as a 2028 problem have the timeline wrong.
The 2027 measurement year begins in 2027. Data collection, provider education, clinical workflow integration, and reporting infrastructure need to be operational before measurement begins — not after. For a measure that requires active screening, documented follow-up, and clinical coordination between behavioral and physical health providers, two years of preparation is not comfortable lead time.
The debit card clarification adds a near-term compliance build. The rule requires supplemental benefit debit cards to be electronically linked to plan-covered items and services through a real-time point-of-sale identification mechanism. Plans using debit card administration need to confirm their current infrastructure supports this now.
The rescission of the mid-year unused supplemental benefit notice removes a regulatory obligation — but introduces a member engagement gap. Plans that relied on that notice as their primary mechanism for communicating benefit availability now need an alternative strategy before utilization rates decline.
Work stream 1 — Deconstruction. Health equity infrastructure built for HEI and QI program requirements must be reviewed. Plans need a documented governance decision — not a passive withdrawal.
Work stream 2 — Protection gap. Eleven eliminated star measures still exist in program audit protocols. Compliance teams need an audit crosswalk before operational investment is reduced in any of those areas.
Work stream 3 — New build. Depression Screening infrastructure, debit card POS linkage, and member engagement strategy for supplemental benefits all need active planning for 2027 — not 2028.
Until next week, stay briefed.